36
Participants
Start Date
February 27, 2020
Primary Completion Date
July 7, 2022
Study Completion Date
October 13, 2022
ART24
Each ART24 capsule will contain lyophilized ART24 and inactive excipients. ART24 will be supplied in a dose strength of 5×10\^9 CFU/capsule. Subjects will receive 1 capsule daily.
Placebo
Each placebo capsule is identical in appearance, weight, and packaging to ART24 capsules, but will contain only the inactive excipients. Subjects will receive 1 capsule daily.
NYU Grossman School of Medicine, New York
Weill Cornell Medicine, New York
Montefiore Medical Center, The Bronx
DiGiovanna Institute, Massapequa
Frontier Clinical Research, LLC, Uniontown
Doral Medical Research, Doral
Gastro Florida, Clearwater
Mayo Clinic, Rochester
Mercury Street Medical Group, Butte
Louisiana Research Center, Shreveport
Advanced Clinical Research, Riverton
Palmtree Clinical Research, Palm Springs
Brigham and Women's Hospital, Boston
Foothills Medical Centre, Calgary
Intermed Groupe Sante, Chicoutimi
Lead Sponsor
Adiso Therapeutics
INDUSTRY